Rifabutin-Containing Triple Therapy Versus Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter, Randomized Controlled Trial
The Journal of Infectious Diseases · 2023
DOI: 10.1093/infdis/jiad114 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, 2023. Verfasst von Jinnan Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, NHC Key Laboratory of Digestive Diseases; Renji Hospital, Shang…. Hauptthemen laut MEDLINE: Helicobacter pylori, Helicobacter Infections. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Jiaotong University.
Abstract (Originalsprache)
Background
We compared the efficacy and safety of rifabutin-containing triple therapy with bismuth quadruple therapy for rescue treatment of Helicobacter pylori.
Methods
This was a noninferiority study trial of H. pylori treatment for subjects who had failed at least 2 prior treatments. Subjects were randomly assigned to receive rifabutin triple therapy with 14-day esomeprazole (20 mg), amoxicillin (1.0 g), and rifabutin (150 mg) twice a day; or bismuth quadruple therapy with esomeprazole (20 mg) and bismuth (220 mg) twice a day, plus metronidazole (400 mg) and tetracycline (500 mg) 4 times a day. Antimicrobial susceptibility was assessed by agar dilution and E-test.
Results
From May 2021 to October 2022, a total of 364 subjects were randomized. The eradication rates by intention-to-treat, per-protocol, and modified intention-to-treat were 89.0% (162/182; 95% confidence interval [CI], 83.6%–92.8%), 94.0% (157/167; 95% CI, 89.3%–96.7%), and 93.6% (162/173; 95% CI, 89.0%–96.4%) for rifabutin triple group. For bismuth quadruple group, they were 89.6% (163/182; 95% CI, 84.3%–93.2%), 95.3% (143/150; 95% CI, 90.7%–97.7%), and 93.7% (163/174; 95% CI, 89.0%–96.4%).
Conclusions
The rifabutin triple therapy is an alternative to classical bismuth quadruple therapy for the rescue treatment of H. pylori with fewer side effects and higher compliance. Clinical Trials Registration NCT04879992.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, NHC Key Laboratory of Digestive Diseases; Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
- Department of Gastroenterology, Shanghai Songjiang District Central Hospital, Shanghai, China.
- Department of Gastroenterology, The Second Affiliated Hospital of Zhejiang University school of Medicine, Hangzhou, China.
ORCID-Profile: Hong Lu
Förderung
- National Natural Science Foundation of China
- Shanghai Jiaotong University
Zitieren
APA
Chen, J., Guo, Y., Huang, Y., Ding, Z., Wang, J., Liang, X., Xu, P., Han, Y., & Lu, H. (2023). Rifabutin-Containing Triple Therapy Versus Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter, Randomized Controlled Trial. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad114
Vancouver
Chen J, Guo Y, Huang Y, Ding Z, Wang J, Liang X, et al. Rifabutin-Containing Triple Therapy Versus Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter, Randomized Controlled Trial. The Journal of Infectious Diseases. 2023. doi:10.1093/infdis/jiad114
BibTeX
@article{Chen2023,
author = {Chen, Jinnan and Guo, Yixian and Huang, Yu and Ding, Zhaohui and Wang, Jing and Liang, Xiao and Xu, Ping and Han, Yaohua and Lu, Hong},
title = {Rifabutin-Containing Triple Therapy Versus Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter, Randomized Controlled Trial},
journal = {The Journal of Infectious Diseases},
year = {2023},
doi = {10.1093/infdis/jiad114}
}
EUVIMED